Biomarkers for prostate cancer

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 10106854
APP PUB NO 20150152507A1
SERIAL NO

14407541

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present application concerns methods and tools for diagnosing prostate cancer and furthermore concerns methods and tools for prognosing disease progression of prostate cancer. The method comprises determining methylation level of the genes C1orf114, HAPLN3, AOX1, GAS6, ST6GALNAC3 and ZNF660 and comparing the result with a control, thus obtaining a response which is used for diagnosing a prostate cancer and/or for prognosing aspects of an individual suffering from prostate cancer.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
AARHUS UNIVERSITETAARHUS AARHUS REGION MIDTJYLLAND

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Ørntoft, Torben Falck Silkeborg, DK 3 13
Haldrup, Christa Nørre Snede, DK 1 0
Sørensen, Karina Dalsgaard Århus C, DK 2 11

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Apr 23, 2026
11.5 Year Payment $7400.00 $3700.00 $1850.00 Apr 23, 2030
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00